| This week's sponsor is Premier Research. | | | >From Lab to Bedside: The Latest in Rare Oncology Drug Research
Study of rare cancers demands immersion in dual indications where strategies often don't mesh. Attend our Feb. 28 webinar for fresh insights on speeding development of new drugs. Register now. Premier Research. It's what we do. Best. |
Featured Story | | | Wednesday, February 15, 2017 Merck has halted a phase 2/3 Alzheimer’s disease trial after an interim analysis found it was destined to fail. The failure of the BACE inhibitor to move the needle in the trial of 2,000 patients with mild-to-moderate Alzheimer’s dented Merck’s stock price after hours and dealt another blow to the amyloid hypothesis. |
|
|
| This week's sponsor is Charles River. | | Webinar: When to Add PDX Models into Your Oncology Program: IO and non-IO?
Could PDX be the most cost-effective tool for targeted therapies in cancer? How can PDX be incorporated into an immuno-oncology program? Can clinical biomarkers be identified using these models?
Just a few of the questions that we'll discuss in our upcoming webinar providing an overview of our extensive experience with PDX models and best ways to use in your preclinical strategy. Join us. |
Top Stories Wednesday, February 15, 2017 VC Versant has pumped $20 million on its own into its newly launched preclinical liver disease upstart Jecure, with its founders coming out from a former Versant biotech. Wednesday, February 15, 2017 Ardelyx has hit its primary endpoint for its key asset tenapanor in a phase 3 hyperphosphatemia test—a much needed positive after years of trial setbacks. Monday, February 13, 2017 An aging population, an ever increasing amount of time viewing digital devices and a growing trend in eye diseases are all factors expected to fuel a global increase in Dry Eye Disease. Wednesday, February 15, 2017 Merck has taken a big step toward getting its lead HIV candidate doravirine to market, setting up a showdown with Johnson & Johnson's big-selling Prezista. Wednesday, February 15, 2017 Inventiva has raised €48 million ($51 million) through an IPO in Paris, France. The offering gives the French biotech, which lists AbbVie and Boehringer Ingelheim among its partners, the cash to take its lead candidate through phase 2b trials in NASH and systemic sclerosis. Wednesday, February 15, 2017 After announcing a never-before-seen deal back in the fall last year that saw contract research organization PRA Health integrate itself into Takeda’s research business, the original pact has been expanded as the CRO will now also work with the Big Pharma in its native Japan under a joint venture deal. Tuesday, February 14, 2017 Spooked by President Donald Trump’s recent skeptical stance on vaccines, more than 350 pro-vaccine groups decided to express their “unequivocal support for the safety of vaccines” to the president. | This week's sponsor is Destination Medical Center. | | | Destination Medical Center (DMC) is a 20-year, $5.6 billion economic development plan set to transform Rochester, MN. DMC and Mayo Clinic are accelerating new advancements in life science research, medical technology, patient care, and education. |
| | | InGeneron's president and CEO Michael Coleman has stepped down, as Ron Stubbers gets promoted to president, with recruitment for a full-time chief now in the works. Release Immunomedics hits out at the "baseless, selfish and shameful lawsuit" filed by venBio this month, as it attempts to stop its multibillion-dollar deal with Seattle Genetics. Statement Auris Medical has announced the pricing of a $10 million public offering coming after a trial setback last year. Release | |
|
Resources Sponsored By: Veeva Learn over a dozen best practices for deploying a global content system. Read Whitepaper. Sponsored By: Veeva Gartner provides insightful research on preparing for IDMP compliance. Read Whitepaper. Sponsored By: Veeva Learn How to Create a Unified RIM Environment for IDMP. Find out. Sponsored By: Veeva The largest survey of TMF owners reveals drivers and trends in improving inspection readiness and shortening trial time. Sponsored By: Salesforce Learn how the healthcare and life science industry is using agile application development to drive innovation and accelerate their business with the Salesforce Platform. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! PEGS: The Essential Protein Engineering Summit May 1-5, 2017 | Boston, MA BIO CEO & Investor Conference February 13 – 14, 2017 | The Waldorf Astoria, New York, NY Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA | 